SecBot SecBot
SECBOTREPLAY Home › Report › LXRX

LXRX · Lexicon Pharmaceuticals reported Q4 2025 financial results with $5.5…

LEXICON PHARMACEUTICALS, INC. · 8-K filed Mar 5, 2026 at 07:02 ET

At the news

BULLISHIMPACT 7/10

8-K filed Mar 5, 2026 at 07:02 ET

Lexicon Pharmaceuticals reported Q4 2025 financial results with $5.5 million in revenue, driven by licensing income from Novo Nordisk and INPEFA sales. The company reduced R&D and SG&A expenses significantly year-over-year, cutting its net loss by over half. It also strengthened its balance sheet with $106.7 million in new cash from a stock sale and a milestone payment. Key pipeline progress includes advancing sotagliflozin for HCM and T1D, and preparing pilavapadin for Phase 3 trials in neuropathic pain.

  • Q4 2025 revenue was $5.5 million, down from $26.6 million in Q4 2024 (primarily due to a $25M upfront payment from Viatris in 2024)
  • Net loss narrowed to $15.5 million in Q4 2025 from $33.8 million in Q4 2024
  • Full-year 2025 net loss was $50.3 million, a 75% improvement from $200.4 million in 2024
  • Received $106.7 million in new cash in February 2026 ($96.7M from stock sale, $10M milestone from Novo Nordisk)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access